Future Contingent Milestone and Royalty Assets (Details) $ in Thousands	1 Months Ended	12 Months Ended
	Feb. 28, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jul. 31, 2022 USD ($)
Schedule of Equity Method Investments [Line Items]
Receivables From Milestone And Royalty Assets Current		$ 50,000
Royalty Pharma
Schedule of Equity Method Investments [Line Items]
Percentage of royalty payments receivable		85.00%	85.00%
Fair value of the contingent consideration				$ 194,200
Receivable for minimum royalty		$ 50,000
Receivables From Milestone And Royalty Assets Current		144,200		$ 194,200
Royalty Pharma | Maximum
Schedule of Equity Method Investments [Line Items]
Payments receivable		$ 250,000	$ 250,000
Royalty Pharma | Subsequent Events
Schedule of Equity Method Investments [Line Items]
Payments receivable	$ 150,000
Proceeds from milestone and royalty assets	$ 50,000
Disposed of by Sale | Royalty Pharma | Discount rate
Schedule of Equity Method Investments [Line Items]
Equity method investment, contingent consideration				7.83